Phase 2 Advanced Non-Small Cell Lung Cancer Clinical Trials
19 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–19 of 19 trials
Recruiting
Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
Squamous Cell CarcinomaAdvanced Non-Small Cell Lung CancerAdvanced NSCLC+2 more
National Cancer Institute (NCI)85 enrolled1 locationNCT02133196
Recruiting
Phase 2
Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC
Locally Advanced Non-Small Cell Lung CancerStage IIIb Non-small Cell Lung CancerStage IIIC Non-Small Cell Lung Cancer
Yang Hong28 enrolled1 locationNCT07309952
Recruiting
Phase 1Phase 2
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
NSCLC (Advanced Non-small Cell Lung Cancer)
BlossomHill Therapeutics266 enrolled41 locationsNCT06706076
Recruiting
Phase 2
Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)
NSCLC (Advanced Non-small Cell Lung Cancer)EGFRMyelosuppression
The First Affiliated Hospital of Xiamen University49 enrolled1 locationNCT06992739
Recruiting
Phase 2
Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
NSCLC (Advanced Non-small Cell Lung Cancer)NSCLC (Non-small Cell Lung Cancer)
Tianjin Medical University Cancer Institute and Hospital20 enrolled1 locationNCT07528274
Recruiting
Phase 2
Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer
NSCLC (Advanced Non-small Cell Lung Cancer)
Gustave Roussy, Cancer Campus, Grand Paris162 enrolled6 locationsNCT07001618
Recruiting
Phase 2
Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer
Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases
Tianjin Medical University Cancer Institute and Hospital74 enrolled1 locationNCT07505173
Recruiting
Phase 2Phase 3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung Cancer
Mirati Therapeutics Inc.806 enrolled764 locationsNCT04613596
Recruiting
Phase 2
ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
NSCLC (Advanced Non-small Cell Lung Cancer)
Fudan University53 enrolled1 locationNCT06775743
Recruiting
Phase 1Phase 2
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
Endometrial CancerGastric (Stomach) CancerNSCLC (Advanced Non-small Cell Lung Cancer)+2 more
Beijing Tide Pharmaceutical Co., Ltd266 enrolled3 locationsNCT07371663
Recruiting
Phase 2
QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC
NSCLC (Advanced Non-small Cell Lung Cancer)
Anhui Provincial Cancer Hospital96 enrolled1 locationNCT07330596
Recruiting
Phase 1Phase 2
A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer
EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Wayshine Biopharm, Inc.100 enrolled12 locationsNCT06631989
Recruiting
Phase 2
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
SafetyLocally Advanced Non-Small Cell Lung CancerThoracic Radiotherapy
JIANYANG WANG44 enrolled1 locationNCT07037680
Recruiting
Phase 1Phase 2
A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
EGFR Mutant Advanced Non-small Cell Lung Cancer
J Ints Bio150 enrolled10 locationsNCT05394831
Recruiting
Phase 2
Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
The Fourth Affiliated Hospital of Zhejiang University School of Medicine20 enrolled1 locationNCT05004974
Completed
Phase 2
Cancer Molecular Screening and Therapeutics (MoST) Program Addendum 17 - substudies 38-39: Tepotinib
Advanced non-small cell lung cancer harbouring MET exon 14 skipping mutations
The University of Sydney32 enrolled12 locationsACTRN12621000811808
Completed
Phase 2
Proof of concept trial alternating lorlatinib with crizotinib in patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer
ALK-rearranged advanced non-small cell lung cancer
Royal North Shore Hospsital25 enrolled2 locationsACTRN12619000844145
Completed
Phase 2
Phase 2 trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced non-small cell lung cancer
EGFR-T790M mutation positive advanced non-small cell lung cancer
University of Sydney50 enrolled14 locationsACTRN12617000720314
Terminated
Phase 2
NIVORAD - A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.
Advanced non-small cell lung cancer, progressing after first of second line chemotherapy
University of Sydney120 enrolled25 locationsACTRN12616000352404